Stoke Therapeutics CMO Barry Ticho Sells Shares

What Happened

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics (STOK), disposed of a total of 5,545 shares on 2026-09-01 via open-market/private sales. The disposals consisted of 3,945 shares at a weighted-average price of $30.51 (totaling $120,370) and 1,600 shares at a weighted-average price of $31.06 (totaling $49,691), for combined proceeds of about $170,061. These were sales (dispositions), not purchases.

Key Details

• Transaction date: 2026-09-01; Form 4 filed: 2026-09-03 (appears timely).
• Lots reported:
  • 3,945 shares sold at a weighted-average price of $30.51 (range $29.94–$30.92) — $120,370.
  • 1,600 shares sold at a weighted-average price of $31.06 (range $30.96–$31.20) — $49,691.
• Total shares sold: 5,545; total proceeds: ~$170,061.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Notable footnotes:
  • F1: Transactions were executed under a Rule 10b5-1 trading plan adopted November 19, 2025.
  • F2/F3: Reported prices are weighted averages; the filer can provide a per-price breakdown on request.
• No indication in this filing that the report was late.

Context

• A Rule 10b5-1 plan is a pre-established trading arrangement that allows insiders to sell shares on a scheduled basis; trades under such plans are often treated as pre-planned and may not reflect a change in the insider’s view on the company.
• Sales are disposals and, by themselves, do not necessarily indicate management sentiment; purchases are generally more informative about bullish conviction.